Drs. Peter Block and Philippe G. Steg discuss cardiovascular outcomes with PCSK9-inhibitor, alirocumab, after acute coronary syndrome.

Keywords: ACC18, ACC Annual Scientific Session, Angina, Stable, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Maximum Tolerated Dose, Brain Ischemia, Stroke, Antibodies, Monoclonal, Angina, Unstable, Apolipoproteins B, Myocardial Infarction, Coronary Disease, Treatment Outcome, Hospitalization, Subtilisins

< Back to Listings